JJ
Jennifer Jarrett (Director, President and CEO) filed 3 Form 4 reports in the trailing twelve months (1 purchase, 2 sales), most often in Arcus Biosciences, Inc. (RCUS). Across 1 priced purchase filing, the average 21-session return was +1.4% from execution and +0.0% from disclosure (delay-adjusted; derived). The largest single filing was $467K of RCUS (21,208 sh across 2 lots, as filed), executed Dec 16 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+1.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+0.0%
same 1 filings, from disclosure
Filings, ttm
3
1 buys · 2 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$720K
shares × price, as filed
Last traded
Sep 25
Filed Sep 28
Median ADV $38.5M across their filed names
Open performance→Volume by month
Buys $253K
Sells $2.2M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
RCUSRecent filings
DMRAPURCHASE
Damora Therapeutics, Inc.
View filing →
$253K12,500 sh × $20.23
Exec Sep 25
Filed Sep 28 · 7:00 AM ET RCUSSALE Arcus Biosciences, Inc. View filing → $467K
21,208 sh across 2 lots
Exec Dec 16 2025
Filed Dec 18 2025 · 5:30 PM ET RCUSSALE Arcus Biosciences, Inc. View filing → $954K
50,291 sh × $18.97
Exec Nov 7 2025
Filed Nov 12 2025 · 5:30 PM ET RCUSSALE Arcus Biosciences, Inc. View filing → $751K
50,292 sh across 2 lots
Exec Oct 6 2025
Filed Oct 8 2025 · 5:30 PM ET